Even though patients with hematologic malignancies are known to have substantial illness burden, poor quality of life, and aggressive care at the end of life, most trials of early palliative care have not included patients with hematologic malignancies, according to a recent review.
When compared to patients with solid tumors, those with hematologic malignancies are more likely to die in the hospital and receive chemotherapy at the end of life, and are less likely to utilize hospice. The authors discuss barriers to palliative care integration in hematology, highlight several reports of successful integration, and suggest specific indications for involving palliative care in the management of hematologic malignancy patients.
LeBlanc T, Roeland E, El-Jawahri A. Early palliative care for patients with hematologic malignancies: Is it really so difficult to achieve? [Published online ahead of print June 21, 2017]. Curr Hematol Malig Rep. doi:10.1007/s11899-017-0392-z.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al